- 1 Severe acute respiratory syndrome coronavirus 2 breakthrough infections in healthcare
- 2 workers vaccinees with BNT162b2 (Pfizer-BioNtech) in Bogotá, Colombia
- 3 Pilar Tavera-Rodríguez^{a†}, Juliana Barbosa-Ramírez^{a†}, Andrea Bermúdez-Forero^{a†}, Diego Prada-
- 4 Cardozo^b, Jhonnatan Reales-González^b, Dioselina Peláez-Carvajal^b, Diana Malo-Sanchez^c, Maria-
- 5 Ximena Meneses-Gil^a, Marcela Mercado-Reyes^a.
- ^a Dirección de Investigación en Salud Pública. Instituto Nacional de Salud, Bogotá 111321, Colombia.
- 7 b Grupo de Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública,
- 8 Instituto Nacional de Salud, Bogotá 111321, Colombia.
- 9 ° Dirección de Vigilancia y Control en Salud Pública. Instituto Nacional de Salud, Bogotá 111321,
- 10 Colombia.

- [†] These authors contributed equally
- 13 Corresponding author: Pilar Tavera-Rodríguez. Email: ptavera@ins.gov.co; Tel.: (+57)
- 14 3133548215; Department of Public Health Research, Instituto Nacional de Salud, Av. Calle 26 No
- 15 51-20, Bogotá 111321, Colombia.
- 17 Abstract
- 18 The healthcare workers are considered as a high-risk group for infection with SARS-CoV-2, so
- they were included in the first stage of the National Plan for Vaccination against COVID-19 in
- 20 Colombia.
- 21 An ongoing prospective cohort study to evaluate immune response to vaccination included 490
- workers from health institutions in Bogotá, Colombia, vaccinated between March and June 2021
- with BNT162b2 (Pfizer-BioNtech). Multiple samples were collected during a follow-up period of
- 24 6 months after immunization. We report cases of asymptomatic and symptomatic SARS-CoV-2

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

infections detected in this cohort. For each participant demographic data, vaccination dates, results for SARS-CoV-2 RT-PCR, and detection of antibody (IgG) tests during the follow-up period were collected. SARS-CoV-2 infection was detected in 38 (7.7 %) volunteers. Of these, 81.6% had a positive RT-PCR for SARS-CoV-2, and 18.4% were confirmed by detection of IgG anti-SARS-CoV-2 nucleoprotein; 76.3% of infections occurred after 7 days of second dose. A total of 57.9% of the cases were asymptomatic. No hospitalizations or deaths were registered. When infection occurred, 81.6% of infected participants had presence of IgG anti-S antibodies. In 12 samples in which genomic characterization was achieved, 83.4% corresponded to the variant Mu, 8.3% Gamma, and 8.3% Delta. All findings agree with other reports in different studies that show the benefit of COVID-19 vaccines, protecting specially against severe disease but not against infection or re-infection. **Keywords:** SARS-CoV-2 infection, health personnel, BNT162b2 vaccine. Background In Colombia the National Plan for Vaccination against coronavirus disease 2019 (COVID-19) started on February 17 2021, with healthcare workers because of the high risk of exposure, using the BNT162b2 COVID-19 vaccine manufactured by Pfizer and BioNTech; healthcare workers at every level and service were included [1]. There are multiple reports about BNT162b2 vaccine efficacy in preventing symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, complications due to infection, and deaths with values above 85% and 90% for symptomatic infection and deaths, respectively [2 - 5]. However, vaccinated individuals are still at risk of infection.

Objectives

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

To report SARS-CoV-2 cases with asymptomatic and symptomatic infections in a cohort of healthcare workers detected during 6–9 months of follow-up after vaccination with BNT162b2. Study design An ongoing prospective cohort study to evaluate the humoral immune response to vaccination included 490 workers from health institutions in Bogotá, Colombia, vaccinated between March and June 2021 with BNT162b2 (Pfizer-BioNTech). Five follow-ups were carried out in 6 months (baseline 0-3 days before vaccination, day 21, 60, 90, and 210 after the first dose) and included the collection of blood samples and a nasopharyngeal swab from participants. Additional follow-up was performed on volunteers who reported symptoms compatible with COVID-19 or close contact with confirmed cases until 9 months after vaccination. This study presents information on cases of SARS-CoV-2 infection detected in the cohort. In addition, for each participant, demographic data, vaccination dates, results for SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR), and detection of antibody (immunoglobulin G [IgG]) tests were collected. The study was approved by the National Health Institute Ethics Committee (CEMIN-4-2021), and all participants signed the informed consent. Anti-S1 IgG was quantified using a SARS-CoV-2 IgG sCOVG chemiluminescence immunoassay (ADVIA Centaur XPT platform, Siemens). In addition, anti-SARS-CoV-2 nucleocapsid IgG presence were determined using the ID Screen®SARS-CoV-2-N indirect enzyme-linked immunosorbent assay (ID Vet). SARS-CoV-2 was detected in nasopharyngeal swabs using real-time RT-PCR to detect the viral E gene [6]. Positive samples by RT-PCR with a cycle threshold (CT) <25 were included in


sequencing [7], assembly of raw data [8], and lineage assignment [9].

Results

SARS-CoV-2 infection was detected in 38 (7.7 %) participants during the follow-up period, with a median age of 40 years (range 26–62); 65.8% (25/38) of them were women. Administrative and laboratory staff had the same frequency (32%), followed by field epidemiologists (29%) and general service staff (8%).

The 78.9% (30/38) of positive cases occurred between May and July 2021; therefore, cases of COVID-19 in healthcare workers described here occurred during the third peak of the disease in Colombia (Figure 1).

Figure 1. Control graph incidence of confirmed SARS-CoV-2 cases, 2021*



^{*} Cases shown corresponds to those confirmed by RT-PCR because cases confirmed by serology do not have a specific date of infection or symptoms onset.

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

A total of 22 out of 38 were asymptomatic. Between the remaining 16 cases, the most frequent symptoms were adynamia (62.5%), headache (43.8%), and fever (37.5%) (Table 1). No hospitalizations or deaths were register. A total of 81.6% of the cases (31/38) had a positive RT-PCR for SARS-CoV-2. Of these, 9.7% (3/31) were detected on the same day as the first dose of the vaccine, 16.1% (5/31) between the first and second doses, and 74.2% (23/31) more than 1 week after the second dose. The remaining seven confirmed cases (18.4%) were positive for anti-nucleoprotein IgG in the serological test. Most of them (6/7) were positive after the second dose of the vaccine. Most cases (81.6%) had IgG anti-S antibodies with values between 56 and 1600 BAU/mL when the infection occurred. The other cases (18.4%) were negative for IgG anti-S antibodies in the sample collected prior to infection confirmation; however, most of these samples were collected between days 0–21 after the first dose of vaccine (Table 2). Genomic characterization was achieved in 38.7% (12/31) of the RT-PCR-positive samples, of which 83.4% (10/12) corresponded to the variant Mu, 8.3% (1/12) Gamma, and 8.3% (1/12) Delta (Table 1). Discussion Within a group of 490 healthcare workers vaccinated against COVID-19 with BNT162b2, 38 cases of SARS-CoV-2 infection were identified, of which 76.3% (29/38) occurred 7 days after the second dose and the time when full efficacy against the disease was reached [2] [10-11]. These results are consistent with previous reports on the high effectiveness of the BNT162b2 vaccine in preventing severe disease and deaths [10 - 12] but lower effectiveness against infection with the virus [4,5, 11, 13, 14].

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

Similar to other reports [13-14], more than 50% of the cases detected were asymptomatic, with no severe cases in infected volunteers. Cases 4 and 19 correspond to people with a previous infection, detected by RT-PCR 6 and 14 months before detection of re-infection during this follow-up. The Colombian third pandemic wave lasted from weeks 10 to 35 (2021), and June had the highest number of cases nationwide in 2021; hence, most cases described concur with this third pandemic peak. During this third peak, genomic surveillance showed that the most frequent variant was Mu (52.7%), followed by the Gamma and lineages (P.1, P.1.1, and P.1.2 with 23.3%) [3]. The viruses sequenced from the cases described herein concur with the predominance of the Mu variant during the third peak (Figure 1), being the variant identified in 83.4% of the samples sequenced. Additionally, the last case detected in December 2021 corresponds to the Delta variant, which started circulating in Colombia in August 2021 [15]. Finally, detection of infection was also possible through anti-N IgG serological tests in seven cases of post-vaccination infection. When the target of the vaccine is the S protein of SARS-CoV-2, the detection of antibodies against a different target, such as nucleoprotein (N), can be used to help differentiate natural infection from vaccination [16-17]. Of these seven people, only one reported having mild respiratory symptoms, while the other six never realized that they had been infected. This dataset was obtained from a well-characterized group of healthcare workers participating in a prospective cohort study that included scheduled follow-ups for collection of respiratory and blood samples and the self-report of clinical symptoms or close contact with confirmed cases of COVID-19. This allows for a very good approach to the assessment of asymptomatic infections. All findings agree with other reports in different studies that show the benefit of COVID-19 vaccines, especially against severe diseases but not against infection or re-infection.

- Acknowledgement: The authors thank Dr. Jaime Castellanos for his review and comments, and
- 135 Hector Ruiz for the figure desing.
- Funding: This research was funded by Instituto Nacional de Salud-Colombia, project code
- 137 CEMIN-04-2021.
- 138 Conflict of Interest: The authors declare no conflict of interest.
- Ethical Approval statement: Informed consent was obtained from all subjects involved in the study.

References

140

- 142 [1] Ministerio de Salud y Protección Social, Departamento Nacional de Planeación, Ministerio
- de Hacienda y Crédito Público, Instituto de Evaluación Tecnológica en Salud. Plan nacional de
- vacunación contra el COVID-19. Documento técnico versión 2. [Internet]. [Accessed: January 19]
- 145 2022]. Available from:
- https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/pnv-contra-covid-19.pdf.
- 147 [2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
- 148 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. December 31
- 2020;383(27):2603-15. doi:10.1056/NEJMoa2034577.
- 150 [3] Instituto Nacional de Salud. Estrategia de caracterización genómica por muestreo
- probabilístico para SARS-CoV-2 en Colombia: Primer muestreo. [Internet]. Available from:
- 152 http://www.ins.gov.co/BibliotecaDigital/Estrategia-caracterizacion-genomica-muestreo-
- probabilistico-SARS-CoV-2-Primer-muestreo.pdf.
- 154 [4] Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine
- coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against
- infection (SIREN): a prospective, multicentre, cohort study. Lancet Lond Engl. May 8
- 2021;397(10286):1725-35. doi: 10.1016/S0140-6736(21)00790-X.

- 158 [5] Zacay G, Shasha D, Bareket R, Kadim I, Hershkowitz Sikron F, Tsamir J, et al. BNT162b2
- 159 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A
- Nationwide Historical Cohort Study. Open Forum Infect Dis. June 1 2021;8(6): ofab262. doi:
- 161 0.1093/ofid/ofab262.
- 162 [6] Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
- 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance [Internet]. 23 de
- 164 enero de 2020 [Accessed February 21 2022];25(3). Available from:
- https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045.
- 166 [7] Quick J. nCoV-2019 sequencing protocol v3 (LoCost) [Internet]. protocols.io. 2020
- 167 [Accessed April 8 2022]. Available from: https://www.protocols.io/view/ncov-2019-sequencing-
- protocol-v3-locost-bh42j8ye.
- Loman N, Rowe W, Rambaut A. nCoV-2019 novel coronavirus bioinformatics protocol.
- [Internet]. [Accessed April 8 2022]. Available from: https://artic.network/ncov-2019/ncov2019-
- bioinformatics-sop.html.
- 172 [9] GitHub cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome
- 173 sequences to global lineages. [Internet]. [Accessed: April 8 2022]. Available:
- 174 https://github.com/cov-lineages/pangolin.
- 175 [10] Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
- Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. November
- 4 2021;385(19):1761-73. Doi: 10.1056/NEJMoa2110345.
- 178 [11] International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health,
- World Health Organization. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing
- 180 Systematic Review. Forest Plots Updated October 21, 2021. [Internet]. Available from:

- 181 https://view-hub.org/sites/default/files/2021-
- 182 10/COVID19%20VE%20Studies Forest%20Plots 1.pdf.
- 183 [12] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and
- effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases,
- 185 hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an
- observational study using national surveillance data. The Lancet. May 2021;397(10287):1819-29.
- doi: 10.1016/S0140-6736(21)00947-8.
- 188 [13] Tang L, Hijano DR, Gaur AH, Geiger TL, Neufeld EJ, Hoffman JM, et al. Asymptomatic
- and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened
- 190 Workforce. JAMA. June 22 2021;325(24):2500-2502. doi: 10.1001/jama.2021.6564.
- 191 [14] Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association Between
- 192 Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2
- 193 Infections Among Health Care Workers. JAMA. June 22 2021;325(24):2457-65. doi:
- 194 10.1001/jama.2021.7152.
- 195 [15] Ministerio de Salud y Protección Social. Variante Delta ya es dominante en todo el país
- 196 [Internet]. [Accessed February 21 2022]. Available from:
- 197 https://www.minsalud.gov.co/Paginas/Variante-Delta-ya-es-dominante-en-todo-el-pais.aspx.
- 198 [16] CDC. Interim Guidelines for COVID-19 Antibody Testing [Internet]. Centers for Disease
- 199 Control and Prevention. 2020 [Accessed February 21 2022]. Available from:
- 200 https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.
- 201 [17] World Health Organization. Interim recommendations for use of the Pfizer-BioNTech
- 202 COVID-19 vaccine, BNT162b2, under Emergency Use Listing [Internet]. [Accessed February 28
- 203 2022]. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-
- vaccines-SAGE recommendation-BNT162b2-2021.1.

Table 1. Information for cases of SARS-CoV-2 infection confirmed by RT-PCR

Case	Sex / Age range	Occupation / activity	Date of positive result (Epi week - year)	Days after 1st dose	Symptoms	Variant / Lineage	Anti-S IgG (BAU/ml)§
1	F/ 25-34	Field epidemiology	21 - 2021	78	Cough, runny nose, fever, headache, adynamia, ageusia	Mu (B.1.621)	>2180
2	F/ 25-34	Field epidemiology	20 - 2021	74	Asymptomatic	Gamma (P.1)	>2180
3	M/ 35-44	Laboratory	19 - 2021	0	Asymptomatic	Mu (B.1.621)	No Reactive
4	M/ 45-54	General services	19 - 2021	0	Asymptomatic	Mu (B.1.621)	288.9
5	F/ 45-54	General services	19 - 2021	0	Fever, adynamia, myalgia	NS	No Reactive
6	F/ 35-44	Laboratory	22 - 2021	34	Asymptomatic	NS	670.6
7	F/ 35-44	Administrative	22 - 2021	20	Asymptomatic	NS	93.1
8	F/ 25-34	Administrative	22 - 2021	20	Headache, adynamia, anosmia, ageusia	Mu (B.1.621)	56.7
9	F/ 25-34	Laboratory	23 - 2021	95	Asymptomatic	NS	570.7
10	M/ 45-54	Administrative	20 - 2021	8	Asymptomatic	NS	No Reactive
11	M/ 35-44	Laboratory	21 - 2021	14	Headache, adynamia, fever, arthralgia, eye pain, cough, fatigue	NS	No Reactive
12	M/ 45-54	Laboratory	24 - 2021	32	Asymptomatic	Mu (B.1.621)	No Reactive
13	F/ 45-54	Administrative	24 - 2021	10	Headache, adynamia, anosmia	NS	No Reactive
14	M/ 55-64	Administrative	24 - 2021	35	Fever, sore throat	Mu (B.1.621)	>2180
15	F/ 35-44	Laboratory	24 - 2021	103	Asymptomatic	NS	2775,1
16	F/ 35-44	Administrative	25 - 2021	72	Asymptomatic	Mu (B.1.621)	>2180
17	F/ 35-44	Laboratory	25 - 2021	40	Asymptomatic	Mu (B.1.621)	222.1
18	M/ 45-54	Administrative	25 - 2021	41	Adynamia, runny nose, coryza, myalgia	NS	87.2

19	F/ 35-44	Field epidemiology	25 - 2021	111	Runny nose	NS	>2180
20	F/ 55-64	Laboratory	25 - 2021	111	Asymptomatic	NS	939.1
21	F/ 25-34	Field epidemiology	25 - 2021	111	Asymptomatic	NS	1912.3
22	M/ 25-34	Field epidemiology	25 - 2021	110	Fever, cough, sore throat, adynamia, headache, anosmia, ageusia, arthralgia, runny nose, chest pain, conjunctivitis	Mu (B.1.621)	>2180
23	F/ 25-34	Laboratory	26 - 2021	79	Diarrhea, adynamia, cough	NS	>2180
24	F/ 35-44	Field epidemiology	25 - 2021	106	Headache	NS	>2180
25	M/ 45-54	Administrative	28 - 2021	61	Asymptomatic	Mu (B.1.621)	93.3
26	F/ 25-34	Laboratory	28 - 2021	62	Fever, sore throat, respiratory distress, adynamia	NS	>2180
27	F/ 35-44	Field epidemiology	28 - 2021	132	Anosmia, ageusia, nasal congestión	NS	303.5
28	F/ 25-34	Field epidemiology	25 - 2021	109	Anosmia	NS	>2180
29	F/ 35-44	Field epidemiology	45 - 2021	249	Asymptomatic	NS	88.1
30	M/ 35-44	Field epidemiology	45 - 2021	249	Asymptomatic	NS	258.3
31	M/ 25-34	Field epidemiology	48 - 2021	269	Cough, sore throat, adynamia	Delta (AY.122)	196.9

§ Anti-S IgG reported corresponds to the sample collected prior to date of the positive RT-PCR. Results are expressed as binding antibody units (BAU)/mL. Values ≥ 21.8 BAU/ml are positive.

NS: Failed to sequencing (sequences with coverage less than 70% for lineage assignment by the Pangolin algorithm).

Table 2. Information for cases of SARS-CoV-2 infection confirmed by detection of IgG anti-Nucleoprotein

219

220

221 222

223

Case	Sex / Age	Occupation / activity	Date of positive result (Epi week - year)	Days after 1st dose*	Symptoms	Anti-S IgG (BAU/ml)§
32	F/ 35-44	Laboratory	40 - 2021	> 90	Asymptomatic	>2180
33	F/ 55-64	Laboratory	17 - 2021	0-21	Asymptomatic	No Reactive
34	F/ 35-44	Administrative	28 - 2021	21-60	Asymptomatic	1317.8
35	M/ 55-64	Administrative	32 - 2021	60-90	Asymptomatic	1694.1
36	M/ 45-54	General services	35 - 2021	60-90	Asymptomatic	>2180
37	F/ 35-44	Administrative	48 - 2021	> 90	Headache, runny nose	>2180
38	F/ 55-64	Administrative	47 - 2021	> 90	Asymptomatic	>2180

^{*} Days after 1st dose are approximated according to collection date of the positive sample for IgG anti-N

[§] Anti-S IgG reported corresponds to the sample collected prior to date of the positive RT-PCR. Results are expressed as binding antibody units (BAU)/mL. Values ≥ 21.8 BAU/ml are positive.